A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)
Public ClinicalTrials.gov record NCT07076121. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Phase 2/3 Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma Harboring Homozygous MTAP Deletion
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to assess the safety and efficacy of Navlimetostat (BMS-986504), a selective, MTA-cooperative PRMT5 inhibitor, in combination with Nab-paclitaxel/Gemcitabine (nab-p/gem) versus placebo in combination with nab-p/gem, in participants with untreated metastatic Pancreatic Ductal Adenocarcinoma (PDAC) with homozygous methylthioadenosine phosphorylase (MTAP) deletion.
Study identification
- NCT ID
- NCT07076121
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2, Phase 3
- Enrollment
- 470 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 23, 2025 (Actual)
- Primary completion
- May 3, 2029 (Estimated)
- Completion
- May 3, 2029 (Estimated)
- Last update posted
- Jun 3, 2026
2025 – 2029
United States locations
- U.S. sites
- 48
- U.S. states
- 25
- U.S. cities
- 41
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic in Arizona - Phoenix | Phoenix | Arizona | 85054 | — |
| Local Institution - 0365 | Tucson | Arizona | 85724 | — |
| Highlands Oncology Group | Springdale | Arkansas | 72762 | — |
| Scripps Green Hospital | La Jolla | California | 92037 | — |
| Local Institution - 0157 | San Francisco | California | 94115 | — |
| Baptist MD Anderson Cancer Center | Jacksonville | Florida | 32207 | — |
| Mayo Clinic in Florida | Jacksonville | Florida | 32224 | — |
| Winship Cancer Institute, Emory University | Atlanta | Georgia | 30322 | — |
| Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital | Marietta | Georgia | 30060 | — |
| St. Luke's Cancer Institute: Boise | Boise | Idaho | 83712 | — |
| Local Institution - 0168 | Chicago | Illinois | 60637 | — |
| Local Institution - 0125 | Westwood | Kansas | 66205 | — |
| Local Institution - 0370 | Louisville | Kentucky | 40202 | — |
| Local Institution - 0371 | Baltimore | Maryland | 21201 | — |
| Johns Hopkins Hospital | Baltimore | Maryland | 21287 | — |
| Local Institution - 0120 | Boston | Massachusetts | 02215 | — |
| Brigitte Harris Cancer Pavilion | Detroit | Michigan | 48202 | — |
| The Cancer & Hematology Centers | Grand Rapids | Michigan | 49503 | — |
| Mayo Clinic in Rochester, Minnesota | Rochester | Minnesota | 55905 | — |
| University Of Nebraska Medical Center | Omaha | Nebraska | 68105 | — |
| Roswell Park Cancer Institute | Buffalo | New York | 14263 | — |
| Northwell Health/ RJ Zuckerberg Cancer Center | Lake Success | New York | 11042 | — |
| Laura and Isaac Perlmutter Cancer Center at NYU Langone | Mineola | New York | 11501 | — |
| NYU Winthrop Hospital | Mineola | New York | 11501 | — |
| Icahn School of Medicine at Mount Sinai | New York | New York | 10029 | — |
| Local Institution - 0279 | New York | New York | 10065 | — |
| Wilmot Cancer Institute | Rochester | New York | 14642 | — |
| University of North Carolina Medical Center | Chapel Hill | North Carolina | 27514 | — |
| Local Institution - 0376 | Columbus | Ohio | 43210 | — |
| Kaiser Permanente Center for Health Research | Portland | Oregon | 97227 | — |
| Local Institution - 0162 | Portland | Oregon | 97239 | — |
| St. Luke's University Health Network | Bethlehem | Pennsylvania | 18015 | — |
| Local Institution - 0301 | Lancaster | Pennsylvania | 17601 | — |
| Thomas Jefferson University - Medical Oncology | Philadelphia | Pennsylvania | 19107 | — |
| Local Institution - 0368 | Pittsburgh | Pennsylvania | 15212 | — |
| UPMC Hillman Cancer Center | Pittsburgh | Pennsylvania | 15232 | — |
| SCRI Oncology Partners | Nashville | Tennessee | 37203 | — |
| Tennessee Oncology, PLLC | Smyrna | Tennessee | 37167 | — |
| Texas Oncology - DFW | Dallas | Texas | 75246 | — |
| Uus Oncology | Fort Worth | Texas | 76177 | — |
| University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Local Institution - 0170 | Temple | Texas | 76508 | — |
| LDS Hospital | Salt Lake City | Utah | 84143 | — |
| Inova Schar Cancer Institute | Fairfax | Virginia | 22031 | — |
| Local Institution - 0348 | Norfolk | Virginia | 23502 | — |
| Local Institution - 0169 | Seattle | Washington | 98101 | — |
| Fred Hutchinson Cancer Center | Seattle | Washington | 98109 | — |
| Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 221 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07076121, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 3, 2026 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT07076121 live on ClinicalTrials.gov.